Clinical Trials Logo

Clinical Trial Summary

This study aims to address the following objectives: 1. To determine the efficacy of IC14, an anti-CD14 chimeric monoclonal antibody, in patients hospitalized with respiratory disease and hypoxemia due to SARS-CoV-2, in terms of improving the time to resolution of disease. 2. To determine the efficacy of IC14 in reducing the severity of respiratory disease in patients hospitalized with respiratory disease due to SARS-CoV-2. 3. To determine the safety of IC14 in patients hospitalized with respiratory disease due to SARS-CoV-2.


Clinical Trial Description

This is a multicenter, randomized, double-blind, placebo-controlled study of IC14, an antibody to CD14, in reducing the severity of respiratory disease in hospitalized Coronavirus Disease 2019 (COVID-19) patients. Participants will be randomized to IC14 or matching placebo and followed for 60 days after randomization. The study drug will be administered daily on Days 1-4 by intravenous infusion. All participants will receive standard of care antiviral therapy with remdesivir. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04391309
Study type Interventional
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact
Status Terminated
Phase Phase 2
Start date April 12, 2021
Completion date February 4, 2022

See also
  Status Clinical Trial Phase
Completed NCT04516564 - A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects Phase 1
Withdrawn NCT04519424 - CSL324 in COVID-19 Phase 2
Not yet recruiting NCT04395170 - Convalescent Plasma (PC) and Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19. Phase 2/Phase 3
Completed NCT05437289 - A Study to Evaluate the Safety and Tolerability of AZD7442 in Healthy Chinese Adults Phase 1
Completed NCT05594147 - An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib
Withdrawn NCT04848467 - COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older Phase 3
Completed NCT04588363 - COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C
Terminated NCT04877743 - Non-Interventional Enhanced Active Surveillance Study of Adults Vaccinated With AZD1222
Completed NCT04742725 - A Study to Evaluate the Efficacy and Safety of Prothione™ Capsules for Mild to Moderate Coronavirus Disease 2019 (COVID-19) Phase 2
Completed NCT04378777 - Immunophenotyping Assessment in a COVID-19 Cohort
Completed NCT04545047 - Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19
Completed NCT04375761 - COVID-19: Human Epidemiology and Response to SARS-CoV-2
Completed NCT04327206 - BCG Vaccination to Protect Healthcare Workers Against COVID-19 Phase 3
Terminated NCT05375760 - A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19 Phase 2
Completed NCT04344977 - Collection of Anti-SARS-CoV-2 Immune Plasma
Terminated NCT04389840 - Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure Phase 2/Phase 3
Withdrawn NCT04425733 - MK-5475 in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009) Phase 1
Not yet recruiting NCT04438837 - Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers N/A
Completed NCT04409509 - Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19) Phase 2
Completed NCT04275245 - Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia Phase 1/Phase 2